Faculty Opinions recommendation of B-type natriuretic peptides help in cardioembolic stroke diagnosis: pooled data meta-analysis.

2016 ◽  
Author(s):  
Scott Kasner
Keyword(s):  
Natriuretic Peptides ◽  
Meta Analysis ◽  
Cardioembolic Stroke ◽  
Pooled Data ◽  
Stroke Diagnosis

scholarly journals B-Type Natriuretic Peptides Help in Cardioembolic Stroke Diagnosis

Stroke ◽  
2015 ◽  
Vol 46 (5) ◽  
pp. 1187-1195 ◽  
Author(s):  
Víctor Llombart ◽  
Albert Antolin-Fontes ◽  
Alejandro Bustamante ◽  
Dolors Giralt ◽  
Natalia S. Rost ◽  
...  
Keyword(s):  
Natriuretic Peptides ◽  
Meta Analysis ◽  
Area Under The Curve ◽  
Cardioembolic Stroke ◽  
Blood Levels ◽  
Clinical Value ◽  
Predictive Values ◽  
Pubmed Database ◽  
Integrated Discrimination Improvement ◽  
Improvement Index

Background and Purpose— Determining the underlying cause of stroke is important to optimize secondary prevention treatment. Increased blood levels of natriuretic peptides (B-type natriuretic peptide/N-terminal pro-BNP [BNP/NT-proBNP]) have been repeatedly associated with cardioembolic stroke. Here, we evaluate their clinical value as pathogenic biomarkers for stroke through a literature systematic review and individual participants’ data meta-analysis. Methods— We searched publications in PubMed database until November 2013 that compared BNP and NT-proBNP circulating levels among stroke causes. Standardized individual participants’ data were collected to estimate predictive values of BNP/NT-proBNP for cardioembolic stroke. Dichotomized BNP/NT-proBNP levels were included in logistic regression models together with clinical variables to assess the sensitivity and specificity to identify cardioembolic strokes and the additional value of biomarkers using area under the curve and integrated discrimination improvement index. Results— From 23 selected articles, we collected information of 2834 patients with a defined cause. BNP/NT-proBNP levels were significantly elevated in cardioembolic stroke until 72 hours from symptoms onset. Predictive models showed a sensitivity >90% and specificity >80% when BNP/NT-proBNP were added considering the lowest and the highest quartile, respectively. Both peptides also increased significantly the area under the curve and integrated discrimination improvement index compared with clinical models. Sensitivity, specificity, and precision of the models were validated in 197 patients with initially undetermined stroke with final pathogenic diagnosis after ancillary follow-up. Conclusions— Natriuretic peptides are strongly increased in cardioembolic strokes. Future multicentre prospective studies comparing BNP and NT-proBNP might aid in finding the optimal biomarker, the best time point, and the optimal cutoff points for cardioembolic stroke identification.

scholarly journals Erythropoietin monotherapy for neuroprotection after neonatal encephalopathy in low-to-middle income countries: a systematic review and meta-analysis

2021 ◽  
Author(s):  
Phoebe Ivain ◽  
Paolo Montaldo ◽  
Aamir Khan ◽  
Ramyia Elagovan ◽  
Constance Burgod ◽  
...  
Keyword(s):  
Meta Analysis ◽  
Neonatal Encephalopathy ◽  
Neurodevelopmental Outcomes ◽  
Term Infants ◽  
Middle Income ◽  
Middle Income Countries ◽  
Pooled Data ◽  
Risk Of Death ◽  
Low Middle Income Countries ◽  
Near Term

Abstract Objective We examined whether erythropoietin monotherapy improves neurodevelopmental outcomes in near-term and term infants with neonatal encephalopathy (NE) in low-middle income countries (LMICs). Methods We searched Pubmed, Embase, and Web of Science databases to identify studies that used erythropoietin (1500–12,500 units/kg/dose) or a derivative to treat NE. Results Five studies, with a total of 348 infants in LMICs, were retrieved. However, only three of the five studies met the primary outcome of death or neuro-disability at 18 months of age or later. Erythropoietin reduced the risk of death (during the neonatal period and at follow-up) or neuro-disability at 18 months or later (p < 0.05). Death or neuro-disability occurred in 27.6% of the erythropoietin group and 49.7% of the comparison group (risk ratio 0.56 (95% CI: 0.42–0.75)). Conclusion The pooled data suggest that erythropoietin monotherapy may improve outcomes after NE in LMICs where therapeutic hypothermia is not available.

scholarly journals Natriuretic peptides and troponins in pulmonary embolism: a meta-analysis

Thorax ◽  
2009 ◽  
Vol 64 (10) ◽  
pp. 869-875 ◽  
Author(s):  
J-C Lega ◽  
Y Lacasse ◽  
L Lakhal ◽  
S Provencher
Keyword(s):  
Pulmonary Embolism ◽  
Natriuretic Peptides ◽  
Meta Analysis

scholarly journals Preoperative B-type natriuretic peptides in patients undergoing noncardiac surgery: a cumulative meta-analysis

2015 ◽  
Vol 21 (4) ◽  
pp. 96-106
Author(s):  
Lisa Ryan ◽  
Chantal Rajah ◽  
Dale Simmers ◽  
Danielle Potgieter ◽  
Reitze N. Rodseth
Keyword(s):  
Natriuretic Peptides ◽  
Meta Analysis ◽  
Noncardiac Surgery

Abstract P111: Comparative Efficacy Of Bisoprolol Compared To Other Selective Beta-1 Blockers In Patients With Hypertension - A Systematic Review And Meta-analysis Of Observational Studies

Hypertension ◽  
2021 ◽  
Vol 78 (Suppl_1) ◽  
Author(s):  
Uday M Jadhav ◽  
Tiny Nair ◽  
SANDEEP BANSAL ◽  
Saumitra Ray
Keyword(s):  
Lipid Profile ◽  
Observational Studies ◽  
Clinical Decision Making ◽  
Meta Analysis ◽  
Hdl Cholesterol ◽  
Clinical Decision ◽  
Cochrane Library ◽  
Favourable Effect ◽  
Pooled Data ◽  
Cholesterol Levels

Introduction: Selective beta-1 blockers (s-BBs) are used in the management of hypertension (HT) in specific subsets. Studies comparing the potency of blood pressure (BP) lowering with different s-BBs are sparse. The objective of this meta-analysis was to evaluate the efficacy of bisoprolol compared to other s-BBs (Atenolol, Betaxolol, Esmolol, Acebutolol, Metoprolol, Nebivolol) in HT patients by examining their effect on BP, heart rate (HR) and metabolic derangements, by examining the evidences reported in observational studies. Methods: Electronic databases like PubMed, EMBASE, Cochrane Library, Clinicaltrials.gov, Surveillance, Epidemiology and End Results Program and 12 PV databases were systematically searched from inception to October 2019. Observational studies that compared bisoprolol with other s-BBs in patients with HT were evaluated in accordance with the PRISMA guidelines. Pooled data were calculated using random-effects model for meta-analysis in terms of mean difference (MD) and 95% confidence interval (95% CI) for each outcome. Outcomes of interest were BP, HR and lipid profile. Results: Four observational studies which compared bisoprolol with other s-BBs (nebivolol and atenolol) were included in this meta-analysis. Significant reduction was observed in office diastolic BP [MD: -1.70; 95% CI: -2.68,-0.72; P <0.01] among arterial HT patients treated with bisoprolol for 26 weeks (w) compared to those treated with other s-BBs. HT patients treated with bisoprolol for 26 w showed significant reduction in HR [MD: -2.20; 95% CI: -3.57,-0.65; P <0.01] and office HR [MD: -2.55; 95% CI: -3.57,-1.53; P <0.01] than other s-BBs. HDL cholesterol levels increased significantly in essential HT patients treated with bisoprolol at 26 w [MD: 7.17; 95% CI: 1.90,12.45; P <0.01], 78 w [MD: 11.70; 95% CI: 4.49,18.91; P <0.01] and 104 w [MD: 10.20, 95% CI: 4.49,18.91; P <0.01] compared to other s-BBs. Conclusion: Our results suggests that bisoprolol is superior to other s-BBs in reducing BP and HR. Bisoprolol also had a favourable effect on lipid profile shown by increase in HDL cholesterol. This meta-analysis emphasizes the efficacy of bisoprolol over other s-BBs, which aids clinical decision making in treatment of patients with HT.

scholarly journals Association of XPC Polymorphisms with Cutaneous Malignant Melanoma Risk: Evidence from a Meta-Analysis

2020 ◽  
Vol 63 (3) ◽  
pp. 101-112
Author(s):  
Fatemeh Asadian ◽  
Seyed Mohammadreza Niktabar ◽  
Yaser Ghelmani ◽  
Shadi Kargar ◽  
Elahe Akbarian ◽  
...  
Keyword(s):  
Malignant Melanoma ◽  
Meta Analysis ◽  
Complementation Group ◽  
Cutaneous Malignant Melanoma ◽  
Case Control Studies ◽  
Melanoma Risk ◽  
Pooled Data ◽  
Increased Risk ◽  
Pcr Rflp ◽  
Rflp Assay

Background: A number of studies have reported that the xeroderma pigmentosum complementation group C (XPC) polymorphisms are associated with cutaneous malignant melanoma (CMM) susceptibility. But the results of those studies were inconsistent. Here, we performed a study to obtain a more conclusive result on the association of XPC polymorphisms with risk of CMM. Methods: The XPC Lys939Gln and Ala499Val polymorphisms were genotyped in 150 CMM cases and 150 controls by PCR-RFLP assay. Subsequently, all published relevant studies were identified through a comprehensive literature search in PubMed, Web of Science, and CNKI databases. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated to estimate the strength of correlation. Results: There was no significant association between XPC Lys939Gln and Ala499Val polymorphisms and CMM risk in our population. A total of 15 case-control studies including ten studies with 5,990 cases and 7,697 controls on XPC Lys939Gln and five studies with 3,139 cases and 3,721 controls on XPC Ala499Val polymorphism were selected. Pooled data revealed that XPC Lys939Gln (C vs. A: OR = 1.108, 95% CI 1.008– 1.217; P = 0.033) and Ala499Val (C vs. A: OR = 0.918, 95% CI 0.850–0.992; p = 0.031; CC+CA vs. AA: OR = 0.904, 95% CI 0.819–0.997; p = 0.043) polymorphisms were significantly associated with an increased risk of CMM. Moreover, stratified analyses by ethnicity revealed that the XPC Ala499Val and Lys939Gln polymorphisms were significantly associated with risk of CMM in Caucasians and mixed populations, respectively. Conclusions: This meta-analysis result suggested that XPC Lys939Gln and Ala499Val polymorphisms were significantly associated with risk of CMM.

SEARCH PROCEDURE AND DATA EXTRACTION FOR META-ANALYSIS IN BIOMEDICAL RESEARCH

2021 ◽  
Author(s):  
Jasmina Obradovic ◽  
◽  
Vladimir Jurisic
Keyword(s):  
Biomedical Research ◽  
Data Extraction ◽  
Meta Analysis ◽  
Extraction Procedure ◽  
Microsoft Excel ◽  
Pooled Data ◽  
Reference Manager ◽  
Reference Number ◽  
Meta Analyses ◽  
Precise Time

The meta-analysis provides a unique scientific conclusion with precise statistical analysis of pooled data extracted from previously reported relevant studies. That gives a better insight into the current issue with more statistical certainty than any single study observation in biomedical research. Occasionally, meta-analyses don’t provide a precise time for each step of the search strategy. The complete meta-analysis procedure is usually time-consuming, with 6-18 months reported, but it depends on the numbers of collected articles manually reviewed by two or more researchers to prevent potential bias. The purpose of this paper was to present a part of meta-analysis research with a focus on a timeline manner for extraction procedure and suggestions for preparing the database of collected articles. PRISMA guidelines were followed, and Pub Med, Scopus, and ISI Web of Science for the search were used. EndNote reference manager v.7 and Microsoft Excel 2007 were used for base preparation. Results showed that the final reference number was 4918, and 99.88% of them were excluded. A month was necessary for the search of the electronic databases. For reading titles and abstracts and extracting the papers was needed the fourth month. A month was needed for an additional search of bibliographies of the eligible papers. Even with the dedication of the team of reviewers, it is hard to predict the exact time for conducting the meta-analysis, indeed. Our results could be applicable in planning the potential systematic reviews, with or without meta-analysis, and overcoming the obstacles in the single database preparation.

Sign in / Sign up

Export Citation Format

Share Document